AbbVie Inc (ABBV)vsGyre Therapeutics Inc. (GYRE)
ABBV
AbbVie Inc
$294.48
-0.18%
HEALTHCARE · Cap: $521.11B
GYRE
Gyre Therapeutics Inc.
$4.30
+0.94%
HEALTHCARE · Cap: $470.79M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 60012% more annual revenue ($66.01B vs $109.82M). ABBV leads profitability with a 15.7% profit margin vs -19.3%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
GYRE
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$294.48
$137.19 premium
Intrinsic value data unavailable for GYRE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 166.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -13.3% — below average capital efficiency
Revenue declined 2.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : GYRE
The strongest argument for GYRE centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : GYRE
The primary concerns for GYRE are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while GYRE is a turnaround play — different risk/reward profiles.
GYRE carries more volatility with a beta of 4.92 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 25/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary platform that harmoniously combines gene therapy with precision medicine, Gyre is focused on delivering innovative solutions to address significant unmet medical needs. With a robust pipeline and a strong commitment to scientific excellence, the company is well-positioned for sustained growth and impact in the biopharmaceutical sector. Its strategic collaborations and ongoing research and development efforts underscore Gyre's potential to revolutionize treatment paradigms and improve patient outcomes in challenging health conditions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?